Hand sanitizer and surface cleaner company Byotrol had a strong 2020 and are confident about 2021 Watch Now
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sorry lost the end of the esentence:
envelope, the the SP wil rise.
Yes but its stopped now - everything glistening with water drips! Lovely!!
One success and I look forward to an SP of 50p+, bringing us back to a MCAP of £27m.
But the reason the MCAP is so stupidly low is past mis-management. When punters are gradually convinvced the effects of this are past, the drugs really work (not just told they do by G), and the partners are more than jottings on an envelope.
We're being viewed as a startup company until things are proved otherwise.
Great opportunity, but still a lot of risk.
Mathsprof. Your full of joy and expectation. Is it raining where you are?
Let's be hopeful shall we that just one of our 4 products is a success. Lets be honest, and this is not running down any other business, what was the revenue of SNG last year ? Is there MCap determined by revenue or by potential success of one of their products ?
Maybe, our old management Knew how good the products are, and would not accept any old Deal.
Bananaman2 - you say:
The fact that VAL201 is now being used in a collaborative treatment to treat hyperimmune response for COVID19 speaks volumes.
We must be careful as to what this actually means. The partners BlackCat and Oncy are small one-man outfits that don't have funds to do the work. So it is probably still a desktop project until they can get some funding, which I suspect will not occur until after 201 results.
There is a similar problem with 401 and BlackCat. Funds were being looked for many months ago, and the 401 trial results were published almost 3 years ago. Just because the lad that started Blackcat at the end of last year thinks 401 in wonderful, or that BC201 would be a good idea, it doesn't mean anything will come of it!
I'm not saying the projects won't get off the ground, and funding won't come, but I think a good dose of sceptisism is needed.
We can't really tell how much the previous management exaggerated the merits of the drugs until we have some more information.
"VAL201 has been developed in collaboration with Cancer Research (CRUK) and is a decapeptide with potential in treating hormone-dependent and hormone-independent prostate cancer, currently a poorly served multi-billion dollar commercial market."
Take note from the December rns;
" - The results appear, in advance of full analysis, to indicate that the VAL201 compound has a clear impact on patients with prostate cancer, as measured by PSA - evidence that is supported from tumour imaging (MRI and CT) in subjects. The compound has also shown it is very safe and has a high degree of tolerability, up to a dose that is in excess of the predicted dose and any practical therapeutic concentration."
It's really significant that directors now have a proper stake and are on board commercially as well as employees.
I can see this at 18 by next Friday.
Jungamunga. Yes, sorry. I keep having to check. 54m and approx 63m fully diluted but at that point VAL will have approx £3m in the bank.
Also feel that £25m MCap would be about right presently. With the 4 drugs or treatments and some at advanced stages the current valuation seems a way off fair value.
Doog58. Under new leadership and strategy there is a marked change and shareholder centricity. Unfortunately previous events may provide a level of reticence but sentiment is changing and maybe now seeing the value in VAL
I think it's got a lot to do with previously being run as expense account for the directors.
Investors were fleeced so many times , there is understandable reticence.
However things seem so much better now and the science has always been compelling.
Banana , just a slight correction there. We have 54m shares in issue and outstanding warrants are about 9m.
Imo we should be trading at least 40p ( GBP 25m market cap when fully diluted) before the VAL 201 results due in mid September . We have 3 other drugs being developed , collaborations for covid treatment and the Japanese testing one of our drugs for endometriosis.
New candidate drugs also being looked into and a new advisory board of eminent scientist is being put together soon.
Confidence is returning and imo share price could double next week.
what I find really interesting is the fact that there are only 52m shares in issue, increasing to approximately 60m if warrants are exercised.
If things really do turn positive and VAL can achieve success with BC201 and VAL201 for argument sake then you only have to look at the SNG MCap to see whats possible for pharma's.
SNG is currently valued at £350m up from maybe £15m in the early part of the year. I dont like to use this type of comparison but that kind of positive movement would be off the charts. Currently VAL is valued at £7.7m. Why ?
I can remember when GM was doing a Proactive Investor interview some time ago stating that some big boys were monitoring 201 progression, wonder if that is that still the case?
As I questioned yesterday. Is it possible that VAL already have a good idea of the results produced from the trial completed late last year ?
Of course it is. Its their product.
We are now waiting on independent verification of these results which will provide headline information in Q3 or early Q4 if CVD19 has impacted.
The fact that the same drug is used in BC201 treatment speaks volumes also.
Just trying to read between the lines.
Having bought in recently I could see that there was previous negative sentiment towards the leadership. Shareholder action has changed this and the leadership now have been renewed with a renewed focus. Seems to me that VAL is perhaps more than just an undervalued IP owner and may be holding some very lucrative prospects. Nothing has changed in that respect. Same product, new leadership.
Very excited at where this will end up. IMO there is still a way to go before it has comparable MCap. Positive trial updates or licencing really could be unbelievable. Going to try stop thinking about it to much
VAL201 remains on schedule to report headline results in Q3 2020 as detailed in the 19 May 2020 announcement. Source data has been verified using remote access to the clinical trial site, and the important milestone of a “database lock”, being the closure of the database to any further editing, has now been completed.
Data processing and statistical analysis will produce headline results, including an overview of safety and tolerability and indications of disease impact which will be notified to the market in due course.
VAL now fully funded, results due, grossly under value to peers, investors starting to accumulate tranches prior to results being announced to market.
The directors have purchased more shares at a higher price than when they added more a week ago.
Gives a strong clue as to the results shortly to be announced.
Worth a reminder from December rns;
"Positive Phase I/II data compiled"
London, UK., 16 December 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides an update on the clinical progress of VAL201, ValiRx's lead Phase I/II therapeutic compound, for the treatment of prostate cancer and other indications of hormone-induced unregulated growth, including endometriosis.
As the Company anticipated in March 2019, the VAL201 trial is coming to a conclusion. The trial data collected to date is undergoing collation and verification, in addition to statistical and scientific analysis. This is prior to its submission to the relevant regulatory authorities. Until regulatory approval has been reached and all the trial data has been verified, limited preliminary observations can be inferred.
The results appear, in advance of full analysis, to indicate that the VAL201 compound has a clear impact on patients with prostate cancer, as measured by PSA - evidence that is supported from tumour imaging (MRI and CT) in subjects. The compound has also shown it is very safe and has a high degree of tolerability, up to a dose that is in excess of the predicted dose and any practical therapeutic concentration.
The results, along with a full statistical and scientific analysis, will be submitted to the relevant regulatory authorities as is required, at which point the detailed results will be made publicly available. However, in the interim, it is intended that the trial's preliminary observations may be presented at various academic conferences, as part of the compound's ongoing reporting and analysis.
-- All data collected to date during the clinical trial of VAL201, is currently being reviewed and collated by the data analytics team.
-- The data will be secured after it has been entered into the record, collated and verified, whilst some additional data is still to be collected from various providers, contractors and from patients and then entered into the record.
-- Beyond the fundamental safety and tolerability endpoints for the trial, the study is providing accurate pharmacokinetic information about the uptake, distribution, metabolism and elimination of the compound in humans. As such, VAL201 continues to address its endpoints in its first-in-human study.
-- A late-stage study designed to determine the overall effectiveness of VAL201 and the most effective therapeutic strategies for its use in disease management, is now possible. This late-stage study will be designed and set up, in parallel to the conclusion of the current early-stage Phase I/IIa trial.
VAL201 has been developed in collaboration with Cancer Research (CRUK) and is a decapeptide with potential in treating hormone-dependent and hormone-independent prostate cancer, currently a poorly served multi-billion dollar commercial market.
Dr Satu Vanikka, CEO of ValiRx Plc, commented:
"With prostate cancer reported this month in an academic
You're correct Bananaman2, what was holding it back was the mismanagement of the firm and loss of shareholder trust rather than its products, which are very exciting. Now that it seems things have turned for the better, the value and trust is gradually returning. While I have some holding here having accumulated at single digit levels, every time I added more, the history of its management always made me a bit fearful of whether I am taking the right step. Hopefully what's in the pipeline will make me feel one day that I should have added even more when I had the chance.
Bananaman2 thanks for your input, Val has more than 15 years of intellectual property in area of prostrate cancer and now I feel val 201, 301, 401 are all in advanced stage and with covid 19 we will be at the forefront to resolve the need to cure the Covid 19 requirement, in my opinion we have the right management to make Val forward to number 1 just like British Biotech...a truly 100 million market cap by 2022..imo
ST. Further research is exactly what I have been doing this morning. I would suggest to anyone that thinks this is rising based upon hot air to do the same. Thats not the reason I am doing additional research, I want to understand the full potential here and the full potential of not one thing but all products.
I urge anyone that is doing research to read the RNS's related to VAL 201 from 2019, prior to the completion of the trial and the final RNS. I will say no more and leave to peoples own interpretation.
The fact that VAL201 is now being used in a collaborative treatment to treat hyperimmune response for COVID19 speaks volumes.
These are two pieces of news that I am particularly keen to hear more on.
Then we have VAL301 and VAL401 which are equally exciting but perhaps not COVID19 related. However, this does not make them any less exciting.
Cash in the bank, new strategy and leadership and just a £7.7m MCap.
Really starting to dawn on me what could happen here.
Saint fingers crossed. Good BOD here. I took a mighty gamble on Iconic Labs last two days and added after skimming Midatech an hour ago. The AIM is definitely an adrenaline rush. GLA I think Val will come good.
More investors will no doubt be researching into VAL over the weekend
Hopefully Suzy does some media/press.
Another trading day goes by.
Another day closer to results day..